SAGE Therapeutics Inc
F:SG7
Decide at what price you'd be comfortable buying and we'll help you stay ready.
|
S
|
SAGE Therapeutics Inc
F:SG7
|
US |
|
Kenedix Office Investment Corp
TSE:8972
|
JP |
|
C
|
Cyber_Folks SA
WSE:CBF
|
PL |
|
V
|
Veritiv Corp
LSE:0LP2
|
US |
|
R
|
Rashi Peripherals Ltd
NSE:RPTECH
|
IN |
|
F
|
First Tin PLC
LSE:1SN
|
UK |
|
Ford Otomotiv Sanayi AS
IST:FROTO.E
|
TR |
|
A
|
Agilent Technologies Inc
XMUN:AG8
|
US |
|
T
|
Trimble Inc
XMUN:TB5
|
US |
|
R
|
Relx PLC
XMUN:RDEB
|
UK |
|
M
|
Mostostal Zabrze SA
WSE:MSZ
|
PL |
|
Ironman International Ltd
XTSX:IMI
|
CA |
|
P
|
PetroChina Co Ltd
XMUN:PC6
|
CN |
|
Q
|
Quidel Corp
F:QL1
|
US |
|
M
|
Mitsubishi Kakoki Kaisha Ltd
F:893
|
JP |
|
Telenor ASA
OSE:TEL
|
NO |
|
Match Group Inc
NASDAQ:MTCH
|
US |
|
Elecnor SA
OTC:ELNRF
|
ES |
|
California Resources Corp
F:1CLD
|
US |
|
LuxExperience BV
F:0FV
|
DE |
|
R
|
Repligen Corp
F:RGN
|
US |
|
S
|
Smartone Telecommunications Holdings Ltd
F:SMA
|
HK |
|
A
|
Acea SpA
XMUN:DCA
|
IT |
Our estimates are sourced from the pool of sell-side and buy-side analysts that we have access to. What you see on other sites is mostly sourced from sell-side analysts.
What is SG7's stock price target?
Not Available
SG7 does not have any price targets made by Wall Street professionals.
What is the Revenue forecast for SAGE Therapeutics Inc?
Projected CAGR
57%
The compound annual growth rate for Revenue over the next 3 years is 57%.